The FTSE 100 medical equipment manufacturer Smith & Nephew faces intensifying shareholder pressure to consider a corporate break-up ahead of its annual results next week, particularly if its struggling orthopaedics
Healthcare7- Page
168Articles
In an unprecedented shift within the underground pharmaceutical market, drug dealers across the UK are diversifying their offerings to include sought-after weight-loss medications alongside traditional illicit substances. The weight-loss injection
British online pharmacies have witnessed extraordinary growth, with some providers reporting up to 300% increase in demand, primarily driven by the surging popularity of weight-loss medications. Market analysis from SpendMapper
Market observers and healthcare analysts are closely monitoring a groundbreaking development in the oncology sector, where a pioneering immunotherapy treatment has demonstrated remarkable longevity in its effectiveness. A patient treated
A significant move in the UK healthcare property sector emerged today as American private equity firm KKR partnered with the Universities Superannuation Scheme (USS) to make a takeover bid for
The NHS is seeking private sector funding to address its deteriorating infrastructure and record-breaking emergency department waiting times. Amanda Pritchard, the organisation’s chief executive, has urged ministers to adopt a
Recent clinical trials have unveiled a significant breakthrough in the potential application of weight-loss medication Semaglutide, marketed as Wegovy, in reducing alcohol consumption. The groundbreaking study demonstrated a remarkable 40%
British pharmaceutical giant AstraZeneca has reported a significant 38% increase in pre-tax profits to £8.7 billion for 2024, driven by robust sales across its cancer, lung, and immunology treatments portfolio.
Danish pharmaceutical giant Novo Nordisk has projected reduced growth for 2025 amidst mounting competition in the weight-loss drugs market from American rivals. The company, renowned for its obesity treatments Ozempic
British pharmaceutical giant GSK has announced its first share buyback programme in over a decade, committing £2 billion to the initiative whilst simultaneously upgrading its long-term sales projections. The FTSE
Spire Healthcare, the UK’s largest private healthcare provider, is witnessing unprecedented growth amid mounting NHS pressures. The FTSE 250-listed organisation has strategically positioned itself as a crucial partner in addressing
British care homes witnessed unprecedented transaction levels in 2024, with American investors leading the charge in one of the few property sectors still delivering robust rental growth. Data from property
Danish pharmaceutical giant Novo Nordisk, Europe’s most valuable listed company, has received a stern reprimand from the Prescription Medicines Code of Practice Authority (PMCPA) for systematically failing to disclose healthcare
The Sackler family and their pharmaceutical enterprise Purdue Pharma have reached a landmark £7.4 billion settlement over their involvement in the US opioid crisis, marking a significant development in one
A groundbreaking clinical trial at University College London (UCL) is poising to transform the landscape of alcohol misuse treatment through the utilisation of dimethyltryptamine (DMT), a potent psychedelic compound. The
British healthcare technology firm Cera has secured a landmark $150 million funding round, propelling the company to coveted unicorn status with a valuation exceeding $1 billion. The fundraising effort, combining
